Khedezla is the brand name for the drug desvenlafaxine, which is a selective serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorder. It was approved by the FDA in July 2013 and is manufactured by Osmotica Pharmaceutical. Desvenlafaxine works by increasing serotonin and norepinephrine levels in the central nervous system. Common side effects include dizziness, nausea, insomnia, and sexual dysfunction. Special precautions are needed if the patient has taken MAO inhibitors recently or is pregnant or breastfeeding.